文献速递皮肤肿瘤

抑制PAI-1阻断PD-L1内吞并改善黑色素瘤对免疫检查点阻断的应答

Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
PubMed 文献 · J Invest Dermatol · 2021-05-14

该研究探讨PAI-1对黑色素瘤细胞表面PD-L1的调控机制。体外、体内及临床标本显示PD-L1表面保留与PAI-1表达负相关;细胞外PAI-1通过网格蛋白介导内吞促使PD-L1溶酶体降解。药理学抑制剂tiplaxtinin抑制PAI-1后表面PD-L1升高,并与抗PD-L1免疫检查点阻断在黑色素瘤同基因小鼠模型中协同增效。

要点

  • PAI-1表达与黑色素瘤细胞表面PD-L1保留呈负相关。
  • 细胞外PAI-1经网格蛋白介导内吞促进PD-L1溶酶体降解。
  • tiplaxtinin抑制PAI-1可升高表面PD-L1并与抗PD-L1治疗协同。

核心结论

  • PAI-1通过促进表面PD-L1的溶酶体降解来调控免疫检查点,抑制PAI-1与抗PD-L1免疫治疗联用可能成为黑色素瘤治疗策略。

研究设计与样本

  • 研究在体外、体内及临床标本中分析PD-L1表面保留与PAI-1表达的相关性,并在黑色素瘤同基因小鼠模型中评估tiplaxtinin与抗PD-L1联合治疗。

主要发现

  • 体外、体内和临床标本中PD-L1的细胞表面保留与PAI-1表达呈负相关。
  • 细胞外PAI-1触发网格蛋白介导的内吞,使表面PD-L1内吞并运输至溶酶体降解,导致表面PD-L1减少。
  • 药理学抑制剂tiplaxtinin抑制PAI-1后,体外和体内质膜PD-L1表达均升高。
  • 在黑色素瘤同基因小鼠模型中,tiplaxtinin靶向PAI-1与抗PD-L1免疫检查点阻断治疗协同增效。

临床怎么用

  • 抑制PAI-1可提高黑色素瘤细胞表面PD-L1水平,为与抗PD-L1免疫检查点阻断联合治疗提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint molecules, especially PD-1 and its ligand PD-L1, act as a major mechanism of cancer immune evasion. Although anti-PD-1/PD-L1 monotherapy increases therapeutic efficacy in melanoma treatment, only a subset of patients exhibits long-term tumor remission, and the underlying mechanism of resistance to PD-1/PD-L1 inhibitors remains unclear. In this study, we demonstrated that cell surface retention of PD-L1 is inversely correlated with PAI-1 expression in vitro, in vivo, and in clinical specimens. Moreover, extracellular PAI-1 induced the internalization of surface-expressed PD-L1 by triggering clathrin-mediated endocytosis. The endocytosed PD-L1 was transported to lysosomes for degradation by endolysosomal systems, resulting in the reduction of surface PD-L1. Notably, inhibition of PAI-1 by pharmacological inhibitor with tiplaxtinin led to elevated PD-L1 expression on the plasma membrane, both in vitro and in vivo. Strikingly, targeting PAI-1 by tiplaxtinin treatment synergizes with anti-PD-L1 immune checkpoint blockade therapy in a syngeneic murine model of melanoma. Our findings demonstrate a role for PAI-1 activity in immune checkpoint modulation by promoting surface PD-L1 for lysosomal degradation and provides an insight into the combination of PAI-1 inhibition and anti-PD-L1 immunotherapy as a promising therapeutic regimen for melanoma treatment.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Tseng YJ, Lee CH, Chen WY, et al. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade. J Invest Dermatol. 2021. PMID: 34000287. doi:10.1016/j.jid.2021.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。